カテゴリ： Allied Market Research, 世界, 医療/バイオ

希少バイオマーカー標本収集・安定化のグローバル市場（2021〜2031）：循環細胞フリーDNA（ccfDNA）、循環腫瘍細胞（CTC）、エキソソーム小胞

■ 英語タイトル：Rare Biomarkers Specimen Collection and Stabilization Market By Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes Vesicles), By Product (Isolation Kits and Reagent, Blood Collection Tubes, Systems), By Application (Oncology, Cardiovascular Diseases, NIPT, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB229）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB229
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：バイオ
■ ページ数：356
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[希少バイオマーカー標本収集・安定化のグローバル市場（2021〜2031）：循環細胞フリーDNA（ccfDNA）、循環腫瘍細胞（CTC）、エキソソーム小胞]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に23,270.04百万ドルであった世界の希少バイオマーカー標本収集・安定化市場規模が、2031年までに54,145.59百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）8.7%で成長すると予測しています。本レポートは、希少バイオマーカー標本収集・安定化の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、種類別（循環細胞フリーDNA（ccfDNA）、循環腫瘍細胞（CTC）、エキソソーム小胞）分析、製品別（分離キット・試薬、採血管、装置）分析、用途別（トランスクリプトミクス、ファーマコゲノミクス、移植拒絶反応、集団スクリーニング、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Agilent Technologies Inc、F Hoffman La Roche、Merck Kgaa、Bio Rad Laboratories、Thermofischer Scientific Inc、Qiagen、Perkin Elmer、Charles River Laboratories International, Inc.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の希少バイオマーカー標本収集・安定化市場規模：種類別
- 循環細胞フリーDNA（ccfDNA）における市場規模
- 循環腫瘍細胞（CTC）における市場規模
- エキソソーム小胞における市場規模
・世界の希少バイオマーカー標本収集・安定化市場規模：製品別
- 分離キット・試薬の市場規模
- 採血管の市場規模
- 装置の市場規模
・世界の希少バイオマーカー標本収集・安定化市場規模：用途別
- トランスクリプトミクスにおける市場規模
- ファーマコゲノミクスにおける市場規模
- 移植拒絶反応における市場規模
- 集団スクリーニングにおける市場規模
- その他における市場規模
・世界の希少バイオマーカー標本収集・安定化市場規模：地域別
- 北米の希少バイオマーカー標本収集・安定化市場規模
- ヨーロッパの希少バイオマーカー標本収集・安定化市場規模
- アジア太平洋の希少バイオマーカー標本収集・安定化市場規模
- 中南米・中東・アフリカの希少バイオマーカー標本収集・安定化市場規模
・企業状況
・企業情報

世界の希少バイオマーカー標本収集・安定化市場の2021年の市場規模は232億7,504万ドルで、2031年には541億4,559万ドルに達すると予測され、2022年から2031年までの年平均成長率は8.7%です。バイオマーカーとは、生物学的状態や病態の測定可能な指標。

通常、血液、尿、軟部組織の測定や評価に使用されます。バイオマーカーは、心拍数や加速度計のデータなどのバイタルパラメータのモニタリングが中心です。希少バイオマーカー標本採取では、血液や体内の他の部位を評価することにより、希少疾患の原因となる微生物を同定します。これらの標本は、さらなる研究のために、分離キット、試薬、その他の機器を使用して安定化されます。バイオマーカーには、分子バイオマーカー、細胞バイオマーカー、画像バイオマーカーがあります。

しかし、バイオマーカーは、決定的な臨床データを収集する前に治療の安全性と有効性に関する情報を提供することで、臨床試験プロセスの負担を軽減することができます。
市場の成長を促進する主な要因は、慢性疾患や遺伝性疾患の有病率の上昇、嚢胞性線維症、筋ジストロフィー、二分脊椎などの希少疾患の発生率の増加、老年人口の増加です。例えば、DNAシーケンシングおよびアレイベース技術の世界的リーダーであるIllumina社は、2022年5月、CEマークを取得した体外診断用医薬品TruSight Oncology (TSO) Comprehensive (EU)検査にコンパニオン診断（CDx）の適応を追加することを発表しました。欧州全域で発売されたこの単一の検査キットは、複数の腫瘍遺伝子とバイオマーカーを評価し、患者のがんの特異的な分子プロファイルを明らかにします。

さらに、承認された希少疾患の新薬上市に向けた研究開発活動の活発化、希少バイオマーカーに対する政府の有利な償還政策、近代的医療施設セクターへの投資の急増、正確な慢性疾患診断に対する需要の高まりなどが、市場の成長を促進すると予想されています。

しかし、政府の規制が厳しく、希少バイオマーカーの標本開発や標準化に関連するコストが高いことが市場成長の妨げとなっています。逆に、発展途上国における医療市場の台頭、薬理ゲノミクスにおける希少バイオマーカー標本の用途の増加、パンデミックや希少遺伝性疾患のリスクの急増は、予測期間中の市場成長に有利な機会を提供すると期待されています。

希少バイオマーカー標本収集・安定化市場は、種類、製品、用途、地域によって区分されます。種類別では、循環遊離DNA、循環腫瘍細胞、エクソソーム小胞に分類されます。製品別では、分離キット＆試薬、採血管、システムに分類されます。用途別では、NIPT、腫瘍学、トランスクリプトミクス、薬理ゲノミクス、移植拒絶反応、集団スクリーニング、心血管疾患、その他に細分化されます。地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

北米は、2021年の希少バイオマーカー標本収集・安定化市場シェアの大半を占めており、予測期間中も支配的であると予測されています。希少バイオマーカー標本採取・安定化市場の主な原動力は、慢性疾患・遺伝性疾患の有病率の上昇、医療費の増加、臨床用・研究用ともに承認された希少バイオマーカー分離キットの急増であり、同地域ではリキッドバイオプシーや生殖補助医療技術の利用が増加し、市場の成長を促進すると予測されています。
アジア太平洋地域は、2021年の市場貢献度第2位であり、予測期間中に最も速いCAGRを記録する見込みです。これは、アンメット・メディカル・ニーズが高く、慢性疾患を治療するための医療インフラが絶えず改善されているためです。さらに、診断、予後、治療モニタリングにおける循環腫瘍細胞（CTC）の有用性を探るための投資の増加は、プレーヤーに有利な成長機会を提供しており、これが市場の成長にさらに貢献すると予想されます。

希少バイオマーカー標本収集・安定化市場で事業を展開する主要企業は、Agilent Technologies、Bio-Rad Laboratories Inc、Charles River Laboratories Inc、F. Hoffman La Roche AG、Merck KGaA、Miltenyi Biotec、Perkin Elmer、Qiagen、Thermofisher Scientific Inc、Siemens AGです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの希少バイオマーカー標本収集・安定化市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、希少バイオマーカー標本収集・安定化市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報を市場調査とともに提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・希少バイオマーカーの標本収集と安定化市場の詳細なセグメンテーション分析により、市場機会を見極めます。
・各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・希少バイオマーカーの標本収集と安定化市場の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
循環遊離細胞DNA（ccfDNA）
循環腫瘍細胞（CTC）
エクソソーム小胞

製品別
単離キット・試薬
採血管
システム

用途別
トランスクリプトミクス
ファーマコゲノミクス
移植拒絶反応
集団スクリーニング
腫瘍
循環器疾患
NIPT
その他

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Agilent Technologies Inc
F Hoffman La Roche
Merck Kgaa
Bio Rad Laboratories
Thermofischer Scientific Inc
Qiagen
Perkin Elmer
Charles River Laboratories International, Inc.
Siemens Healthineers
Eurofins Scientific, Inc.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Circulating Cell Free DNA (ccfDNA)
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Circulating Tumor Cells (CTCs)
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Exosomes Vesicles
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT
5.1 Overview
5.1.1 Market size and forecast
5.2 Isolation Kits and Reagent
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Blood Collection Tubes
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Systems
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oncology
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
6.2.4.1 Research Market size and forecast, by region
6.2.4.2 Diagnostics Market size and forecast, by region
6.3 Cardiovascular Diseases
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 NIPT
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Transcriptomics
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
6.6 Pharmacogenomics
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market analysis by country
6.7 Transplant Rejection
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market analysis by country
6.8 Population Screening
6.8.1 Key market trends, growth factors and opportunities
6.8.2 Market size and forecast, by region
6.8.3 Market analysis by country
6.9 Others
6.9.1 Key market trends, growth factors and opportunities
6.9.2 Market size and forecast, by region
6.9.3 Market analysis by country
CHAPTER 7: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Product
7.2.4 North America Market size and forecast, by Application
7.2.4.1 North America Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Application
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Application
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Application
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Product
7.3.4 Europe Market size and forecast, by Application
7.3.4.1 Europe Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Application
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Application
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Application
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Application
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Application
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Application
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Product
7.4.4 Asia-Pacific Market size and forecast, by Application
7.4.4.1 Asia-Pacific Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Application
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Application
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Application
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Application
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Application
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Application
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Product
7.5.4 LAMEA Market size and forecast, by Application
7.5.4.1 LAMEA Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Application
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Application
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Application
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Application
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Agilent Technologies Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 F Hoffman La Roche
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Merck Kgaa
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bio Rad Laboratories
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Thermofischer Scientific Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Qiagen
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Perkin Elmer
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Charles River Laboratories International, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Siemens Healthineers
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Eurofins Scientific, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR CIRCULATING CELL FREE DNA (CCFDNA), BY REGION, 2021-2031 ($MILLION)
TABLE 3. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR CIRCULATING CELL FREE DNA (CCFDNA), BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR CIRCULATING TUMOR CELLS (CTCS), BY REGION, 2021-2031 ($MILLION)
TABLE 5. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR CIRCULATING TUMOR CELLS (CTCS), BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR EXOSOMES VESICLES, BY REGION, 2021-2031 ($MILLION)
TABLE 7. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR EXOSOMES VESICLES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 9. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR ISOLATION KITS AND REAGENT, BY REGION, 2021-2031 ($MILLION)
TABLE 10. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR ISOLATION KITS AND REAGENT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR BLOOD COLLECTION TUBES, BY REGION, 2021-2031 ($MILLION)
TABLE 12. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR BLOOD COLLECTION TUBES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR SYSTEMS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR SYSTEMS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 16. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR ONCOLOGY, BY REGION, 2021-2031 ($MILLION)
TABLE 17. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL ONCOLOGY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 19. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR RESEARCH, BY REGION, 2021-2031 ($MILLION)
TABLE 20. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR DIAGNOSTICS, BY REGION, 2021-2031 ($MILLION)
TABLE 21. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2031 ($MILLION)
TABLE 22. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR NIPT, BY REGION, 2021-2031 ($MILLION)
TABLE 24. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR NIPT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR TRANSCRIPTOMICS, BY REGION, 2021-2031 ($MILLION)
TABLE 26. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR TRANSCRIPTOMICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR PHARMACOGENOMICS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR TRANSPLANT REJECTION, BY REGION, 2021-2031 ($MILLION)
TABLE 30. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR TRANSPLANT REJECTION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR POPULATION SCREENING, BY REGION, 2021-2031 ($MILLION)
TABLE 32. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR POPULATION SCREENING, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 33. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 34. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 36. NORTH AMERICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. NORTH AMERICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 38. NORTH AMERICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 39. NORTH AMERICA ONCOLOGY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. NORTH AMERICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 41. U.S. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. U.S. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 43. U.S. RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 44. CANADA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. CANADA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 46. CANADA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 47. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 49. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 50. EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 52. EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 53. EUROPE ONCOLOGY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 55. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 56. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 57. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 58. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 59. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 60. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 61. UK RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 62. UK RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 63. UK RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 64. ITALY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 65. ITALY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 66. ITALY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 67. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 68. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 69. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 70. REST OF EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. REST OF EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 72. REST OF EUROPE RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 73. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 74. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 75. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 76. ASIA-PACIFIC ONCOLOGY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 77. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 78. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 79. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 80. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 81. CHINA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 82. CHINA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 83. CHINA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 84. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 85. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 86. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 87. INDIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 88. INDIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 89. INDIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 90. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 91. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 92. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 96. LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 97. LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 98. LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 99. LAMEA ONCOLOGY RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 100. LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 101. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 102. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 103. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 104. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 105. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 106. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 107. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 108. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 109. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 110. REST OF LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 111. REST OF LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 112. REST OF LAMEA RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 113.AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT
TABLE 114.AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS
TABLE 115.AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 116.AGILENT TECHNOLOGIES INC: NET SALES,
TABLE 117.AGILENT TECHNOLOGIES INC: KEY STRATERGIES
TABLE 118.F HOFFMAN LA ROCHE: COMPANY SNAPSHOT
TABLE 119.F HOFFMAN LA ROCHE: OPERATING SEGMENTS
TABLE 120.F HOFFMAN LA ROCHE: PRODUCT PORTFOLIO
TABLE 121.F HOFFMAN LA ROCHE: NET SALES,
TABLE 122.F HOFFMAN LA ROCHE: KEY STRATERGIES
TABLE 123.MERCK KGAA: COMPANY SNAPSHOT
TABLE 124.MERCK KGAA: OPERATING SEGMENTS
TABLE 125.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 126.MERCK KGAA: NET SALES,
TABLE 127.MERCK KGAA: KEY STRATERGIES
TABLE 128.BIO RAD LABORATORIES: COMPANY SNAPSHOT
TABLE 129.BIO RAD LABORATORIES: OPERATING SEGMENTS
TABLE 130.BIO RAD LABORATORIES: PRODUCT PORTFOLIO
TABLE 131.BIO RAD LABORATORIES: NET SALES,
TABLE 132.BIO RAD LABORATORIES: KEY STRATERGIES
TABLE 133.THERMOFISCHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 134.THERMOFISCHER SCIENTIFIC INC: OPERATING SEGMENTS
TABLE 135.THERMOFISCHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 136.THERMOFISCHER SCIENTIFIC INC: NET SALES,
TABLE 137.THERMOFISCHER SCIENTIFIC INC: KEY STRATERGIES
TABLE 138.QIAGEN: COMPANY SNAPSHOT
TABLE 139.QIAGEN: OPERATING SEGMENTS
TABLE 140.QIAGEN: PRODUCT PORTFOLIO
TABLE 141.QIAGEN: NET SALES,
TABLE 142.QIAGEN: KEY STRATERGIES
TABLE 143.PERKIN ELMER: COMPANY SNAPSHOT
TABLE 144.PERKIN ELMER: OPERATING SEGMENTS
TABLE 145.PERKIN ELMER: PRODUCT PORTFOLIO
TABLE 146.PERKIN ELMER: NET SALES,
TABLE 147.PERKIN ELMER: KEY STRATERGIES
TABLE 148.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 149.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 150.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 151.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: NET SALES,
TABLE 152.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATERGIES
TABLE 153.SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 154.SIEMENS HEALTHINEERS: OPERATING SEGMENTS
TABLE 155.SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 156.SIEMENS HEALTHINEERS: NET SALES,
TABLE 157.SIEMENS HEALTHINEERS: KEY STRATERGIES
TABLE 158.EUROFINS SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 159.EUROFINS SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 160.EUROFINS SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 161.EUROFINS SCIENTIFIC, INC.: NET SALES,
TABLE 162.EUROFINS SCIENTIFIC, INC.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 希少バイオマーカー検体採取＆安定化のグローバル市場（2023～2030）：研究、診断
  • 採血のグローバル市場（2021〜2031）：針・注射器、採血チューブ、血液ランセット、血液バッグ、その他
  • 外尿道管理製品のグローバル市場（2021～2031）：男性、女性
  • ポストバイオティクスのグローバル市場（2021〜2031）：粉末、液体、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB229 )"希少バイオマーカー標本収集・安定化のグローバル市場（2021〜2031）：循環細胞フリーDNA（ccfDNA）、循環腫瘍細胞（CTC）、エキソソーム小胞" (英文：Rare Biomarkers Specimen Collection and Stabilization Market By Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes Vesicles), By Product (Isolation Kits and Reagent, Blood Collection Tubes, Systems), By Application (Oncology, Cardiovascular Diseases, NIPT, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。